(PTGX) Protagonist Therapeutics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PTGX) Protagonist Therapeutics, Inc. Complete Analysis Pack
Protagonist Therapeutics: Business Model Blueprint at a Glance
Unlock the full strategic blueprint behind Protagonist Therapeutics, Inc.’s business model. This concise Business Model Canvas highlights how the company creates value, builds partnerships, and positions itself in the biotech market. Ideal for investors, analysts, and strategists who want deeper insight—get the full version to explore every building block.
Partnerships
Janssen Biotech collaboration
Protagonist Therapeutics’ Janssen Biotech, Inc. deal is its clearest named partnership, built on a licensing and collaboration agreement that supports pipeline development and future partnering. The tie-up has been central to advancing assets such as rusfertide, which reached positive phase 3 results in 2024, strengthening Protagonist’s partnered-program value.
Phase II clinical trial sites
Phase II clinical trial sites are core partners for Protagonist Therapeutics, Inc.: hospitals and research centers enroll patients and run studies for 3 key programs, rusfertide, PN-943, and PN-235. In 2025, these sites generated the proof-of-concept data the company needs to decide whether each asset can move into later-stage testing.
Peptide manufacturing partners
Peptide drugs need specialized CMC and scale-up support, so Protagonist Therapeutics, Inc. relies on contract manufacturers for GMP clinical material and quality systems across injectable and oral programs. This matters because its partnered peptide pipeline spans 2 major late-stage assets, making outside manufacturing a core execution risk and capacity lever.
Regulatory agencies
Protagonist Therapeutics, Inc. depends on the FDA and other regulators for every IND and future filing, because clinical work must prove safety, efficacy, and CMC quality. The FDA’s IND review clock is 30 days, so agency feedback can shift trial timing, hold decisions, and the path to approval.
- INDs face a 30-day FDA review
- Safety, efficacy, CMC must align
- Regulators shape timelines and filings
Academic and medical centers
Academic and medical centers give Protagonist Therapeutics direct access to hematology and inflammatory bowel disease experts, which helps shape investigator input, recruit patients, and test translational science in real care settings. That matters because the company ended FY2025 with no commercial product revenue and relied on research execution to advance its pipeline and adoption readiness.
- Expert KOL input
- Faster patient recruitment
- Better trial relevance
- Stronger launch readiness
Protagonist’s Growth Depends on Partners, Regulators, and Manufacturing
Protagonist Therapeutics, Inc. leans on Janssen Biotech, Inc. for its biggest partnered value driver, while FDA review and clinical sites keep programs like rusfertide moving through testing. Contract manufacturers are also key, because peptide supply and GMP scale-up sit outside the company.
| Partner | Role |
|---|---|
| Janssen Biotech, Inc. | Licensing and collaboration |
| FDA | IND and filing review |
| Trial sites | Patient enrollment and studies |
| CMOs | GMP manufacturing |
What is included in the product
Detailed Word Document
A concise Business Model Canvas of Protagonist Therapeutics, Inc. mapping its drug-development strategy, partners, revenue drivers, and competitive position.
Customizable Excel Spreadsheet
Clarifies Protagonist Therapeutics’ business model as a pain reliever, helping teams quickly spot value drivers, partners, and key risks.
Reference Sources
Provides a concise source trail for Protagonist Therapeutics, Inc. to validate claims, boost credibility, and speed investor due diligence.
Activities
Peptide drug discovery
Protagonist Therapeutics, Inc. starts its pipeline with peptide drug discovery, designing peptide-based therapies for hematological and immune-mediated diseases. Its lead asset, rusfertide, is in Phase 3 for polycythemia vera, showing how this activity feeds the company’s first-in-human and late-stage pipeline.
Clinical development in Phase II
Protagonist Therapeutics, Inc. concentrates its Clinical development in Phase II on rusfertide, PN-943, and PN-235, running trials to test safety, dosing, and efficacy before larger studies. This stage is the portfolio’s main value-inflection point, where mid-stage readouts can materially shift program and company valuation.
Translational research
Protagonist Therapeutics, Inc. uses translational research to connect biology, biomarkers, and human data, which helps validate its hepcidin mimetic and receptor-antagonist programs. This work also guides trial design and patient selection across its 2 key clinical mechanisms, so the company can test signal, dose, and response in the right patients.
CMC and manufacturing oversight
Protagonist Therapeutics, Inc. keeps CMC and manufacturing oversight tight because peptide drugs need process development, analytics, and supply control to make the same clinical-grade material every batch. CMC quality matters in trials and later registration, and it supports the company’s 2 late-stage peptide programs by lowering batch risk and data gaps.
- Controls peptide process and release quality
- Protects clinical-grade supply consistency
- Supports trial and registration readiness
Partnering and regulatory management
Protagonist Therapeutics, Inc. relies on active alliance management with Janssen to keep partnered programs moving, while its team steers regulatory plans, briefing books, and milestone filings with the FDA and other agencies. In 2025, this mattered because partnering and filings remained the bridge between clinical data and value creation in a biotech model.
- Janssen collaboration needs ongoing governance
- Regulatory filings drive development milestones
- Partnering is core to biotech revenue creation
These activities protect timelines, support label strategy, and help convert trial wins into commercial optionality.
Protagonist Advances Key Programs Toward Value Creation
Protagonist Therapeutics, Inc. focuses on peptide discovery, translational research, and clinical development across 3 core programs: rusfertide, PN-943, and PN-235. The company also runs CMC oversight to keep clinical-grade supply consistent and trial-ready.
Partner and regulatory work are also key, especially with Janssen collaboration governance and FDA filings that move programs from data to value. These activities support phase progression, label strategy, and future commercial readiness.
What You See Is What You Get
Business Model Canvas
This preview is a real section of the Protagonist Therapeutics, Inc. Business Model Canvas, not a mockup or sample. What you see here is the exact document you’ll receive after purchase, with the same content, structure, and formatting. Once your order is complete, you’ll get full access to the same ready-to-use file, with no hidden changes or surprises.
Resources
Rusfertide (PTG-300)
Rusfertide (PTG-300) is Protagonist Therapeutics, Inc.’s lead injectable hepcidin mimetic and its core hematology asset. In 2025, it remained in late-stage development for polycythemia vera and hereditary hemochromatosis, with the program anchoring the Company’s hematology franchise and the main value driver in the pipeline.
PN-943
PN-943 is Protagonist Therapeutics, Inc.'s oral peptide alpha-4-beta-7 integrin antagonist for inflammatory bowel disease, giving the company a gut-targeted immunology asset. In the latest filings, it remains an R&D-stage program, so it supports pipeline value rather than near-term revenue.
PN-235
PN-235 is Protagonist Therapeutics, Inc.'s oral interleukin-23 receptor antagonist, built for inflammatory bowel disease and other inflammation uses. It strengthens the immunology pipeline beyond rusfertide, and as of 2026 Protagonist Therapeutics, Inc. has not disclosed separate revenue or sales for PN-235 because it remains in development.
Peptide expertise and IP
Protagonist Therapeutics, Inc. builds around peptide discovery and engineering, and its IP protects both the drug candidates and the platform. That moat matters because peptide assets can be tuned for target selectivity and stability, helping Protagonist Therapeutics, Inc. stand apart from small molecules and biologics.
- Core know-how: peptide design
- IP shields platform and assets
- Supports clear differentiation
Scientific team and Newark headquarters
Protagonist Therapeutics, Inc., founded in 2006 and based in Newark, California, relies on its scientific and managerial staff as core operating resources. The Newark headquarters anchors research, business development, and oversight; as of the latest filing, the Company reported 2025 revenue of $132.4 million and ended the year with $1.0 billion in cash, cash equivalents, and marketable securities.
- Founded in 2006
- Headquarters: Newark, California
- 2025 revenue: $132.4 million
- Cash and investments: $1.0 billion
Protagonist Therapeutics: Peptide Platform, Pipeline, and $1B Cash Edge
Protagonist Therapeutics, Inc.’s key resources are its peptide engineering platform, proprietary IP, and late-stage assets led by rusfertide, plus PN-943 and PN-235. The Company also relies on its scientific team and Newark, California base to advance R&D and licensing work. As of 2025, it reported $132.4 million in revenue and $1.0 billion in cash, cash equivalents, and marketable securities.
| Key resource | Why it matters |
|---|---|
| Peptide platform | Drives target design |
| IP portfolio | Protects assets |
| Rusfertide, PN-943, PN-235 | Main pipeline value |
| 2025 cash and investments | $1.0 billion |
Value Propositions
Hepcidin mimetic for blood disorders
Rusfertide is Protagonist Therapeutics, Inc.’s hepcidin mimetic, designed to regulate iron and reduce red blood cell overproduction. In a phase 3 setting, the program has targeted polycythemia vera, which affects about 100,000 people in the U.S., and the same iron-control logic may fit hereditary hemochromatosis, a disorder seen in about 1 in 200 to 1 in 300 people of Northern European descent.
Oral targeted IBD therapy
PN-943 is Protagonist Therapeutics, Inc.’s oral peptide for inflammatory bowel disease, aiming to replace injectable dosing with a simpler daily pill. Gut-selective targeting is the key value prop: it is designed to act in the intestine, where IBD affects about 7 million people worldwide, while limiting broader systemic exposure.
Oral IL-23 pathway blockade
PN-235 is an oral peptide that blocks the IL-23 receptor, hitting a validated inflammatory pathway already proven by IL-23 biologics in psoriasis, psoriatic arthritis, and IBD. If it delivers oral dosing with biologic-like efficacy, it could support use across immune-mediated diseases and reach a much broader patient base than injectables.
Peptide-based specificity
Peptide-based specificity lets Protagonist Therapeutics, Inc. design drugs that bind a narrow target and cut off-target noise, which is why specificity sits at the center of its science. The clearest proof is rusfertide, its 1 Phase 3 program, built around a selective mechanism for polycythemia vera.
- High target binding precision
- Selective mechanism focus
- 1 Phase 3 asset
Pipeline across hematology and immunology
Protagonist Therapeutics spans hematology and immunology, led by rusfertide in Phase 3 for polycythemia vera and icotrokinra in mid- to late-stage immune disease trials. That gives the Company 2 shots on goal in 2 large markets, cuts reliance on one indication, and can create value even if one program misses.
- 2 core disease areas: blood and inflammation
- 1 Phase 3 hematology asset: rusfertide
- Multiple immune-disease readouts add upside
Protagonist’s Peptide Pipeline Targets Big Markets With Precision
Protagonist Therapeutics, Inc. offers peptide drugs built for high target selectivity, with rusfertide in Phase 3 for polycythemia vera, a U.S. market of about 100,000 patients, and oral programs for immune disease. Its edge is simple: more precise biology, less off-target noise, and dosing formats patients may prefer.
| Asset | Value proposition | Key number |
|---|---|---|
| Rusfertide | Selective iron control in PV | Phase 3; ~100,000 U.S. patients |
| PN-943 | Oral gut-selective IBD therapy | ~7 million people with IBD worldwide |
Customer Relationships
Clinical-trial participant engagement
Protagonist Therapeutics, Inc. builds clinical-trial participant engagement through informed consent, protocol-driven site operations, and close safety oversight. Site teams guide patients through study visits and monitoring, and this relationship stays tightly regulated under research rules and ethics review.
Investigator-led scientific collaboration
Protagonist Therapeutics, Inc. relies on physician and investigator input to shape study design, with feedback on endpoints, dosing, and enrollment across its 2 key late-stage programs, rusfertide and icotrokinra. In specialty diseases, KOL ties matter because they help build trial credibility and speed site activation in small patient pools.
Medical affairs support
With no approved product revenue in 2025, Protagonist Therapeutics, Inc. depends on medical affairs to turn late-stage data into trust. Clear scientific exchange with hematologists and partners helps explain Phase 3 results, answer safety questions, and build credibility for pipeline assets before commercialization.
Alliance management with Janssen
Protagonist Therapeutics, Inc. manages the Janssen alliance through formal governance, shared data flows, and milestone tracking, so both sides can move fast on decisions and stay aligned on development. Strong alliance management protects partnership value by reducing delays and keeping program handoffs clean.
- Joint governance supports clear decisions
- Data sharing keeps teams aligned
- Milestones track progress and value
Investor and stakeholder communication
Protagonist Therapeutics, Inc. keeps investors close through trial data, SEC filings, and conference calls, which matter because biotech funding depends on trust. At 2024 year-end, it reported $587.1 million in cash, cash equivalents, and marketable securities, so clear updates help protect that financing base and support strategic backing.
- Data releases drive market trust
- SEC filings keep disclosure current
- Conferences support financing access
Protagonist Builds Trust to Advance Rusfertide and Icotrokinra
Protagonist Therapeutics, Inc. keeps customer ties centered on trial sites, key opinion leaders, and the Janssen partner, using tight governance, safety oversight, and data sharing to move 2 late-stage programs, rusfertide and icotrokinra. With $587.1 million in cash, cash equivalents, and marketable securities at 2024 year-end, transparent updates still matter for trust.
| Customer group | Relationship lever |
|---|---|
| Patients/sites | Consent, monitoring |
| Physicians/KOLs | Trial input, credibility |
| Janssen | Governance, milestones |
Channels
Clinical trial sites
Clinical trial sites are Protagonist Therapeutics, Inc.'s main execution channel: research hospitals and clinics enroll patients, deliver treatment, and handle follow-up. As a clinical-stage biotech, the company runs its late-stage work through these sites, including 2 lead programs in active human testing.
Scientific conferences
Scientific conferences are a key channel for Protagonist Therapeutics, Inc., with data shared at major medical and biotech meetings like hematology and IBD forums. This matters because the company ended 2025 with $1.1 billion in cash, cash equivalents, and marketable securities, so conference visibility helps support clinical momentum without heavy near-term funding pressure.
Peer-reviewed publications
Peer-reviewed publications turn Protagonist Therapeutics, Inc.'s trial data into trusted evidence for clinicians and researchers, explaining mechanism, safety, and efficacy. In 2025, the 293-patient Phase 3 VERIFY study in polycythemia vera gave the Company a strong data base for journal papers that can support adoption and scientific credibility.
Partnering and business development
Protagonist Therapeutics, Inc. uses direct B2B outreach to pursue collaborations and licensing with Janssen and other partners, making this a key channel for non-dilutive value creation. It supports deal flow for assets with external validation, which can turn partnered programs into cash-generating opportunities without issuing new shares.
- Direct outreach to Janssen and peers
- Licensing and collaboration-led monetization
- Non-dilutive capital, less equity dilution
Corporate and investor communications
As of FY2025, Protagonist Therapeutics used press releases, SEC filings, and investor decks to relay updates on rusfertide, its lead phase 3 asset, to capital markets and other stakeholders. These channels matter most before launch because they frame trial timing, funding needs, and readout risk.
- Press releases share key milestones.
- Filings disclose risk and cash use.
- Investor materials shape launch expectations.
Protagonist’s FY2025 Playbook: Trial Sites, Proof, and $1.1B Cash
Protagonist Therapeutics, Inc. mainly reaches patients through clinical trial sites, while scientific meetings and peer-reviewed journals carry its 2025 Phase 3 data from 293 VERIFY patients to doctors and investors. Direct partner outreach and SEC/investor materials also support licensing talks and keep rusfertide milestones visible, backed by $1.1 billion in cash at FY2025 end.
| Channel | FY2025 data |
|---|---|
| Trial sites | 2 lead programs in human testing |
| Evidence | VERIFY: 293 patients |
| Funding | $1.1 billion cash |
Customer Segments
Janssen Biotech
Janssen Biotech is Protagonist Therapeutics' direct collaboration partner and the business customer for licensed innovation and development rights tied to icotrokinra (JNJ-2113). The partner-led model is central to value capture: Janssen funds late-stage work, and the agreement can scale through milestone and royalty economics as the program advances beyond its 2024 Phase 3 start.
Hematologists
Hematologists are the main prescribers and trial investigators for polycythemia vera and iron disorders, so their adoption will shape rusfertide use if approved. Protagonist Therapeutics’ Phase 3 VERIFY study in 293 adults with polycythemia vera shows why their clinical input matters: these specialists help define endpoints, safety use, and real-world uptake.
Gastroenterologists
Gastroenterologists are the core clinical audience for Protagonist Therapeutics, Inc.'s PN-943 and PN-235, since they treat ulcerative colitis and Crohn’s disease. In the U.S., about 2.4 million people live with inflammatory bowel disease, so their prescribing support can drive future uptake.
Patients with blood disorders
Patients with polycythemia vera and hereditary hemochromatosis are the core end users for rusfertide, because their care depends on tighter iron and red-cell control. Polycythemia vera affects about 44,000 people in the U.S., and hereditary hemochromatosis is among the most common inherited disorders in people of Northern European ancestry, with about 1 in 200 to 1 in 300 carrying the main risk variants.
- Direct need: control iron overload.
- Direct need: reduce red-cell excess.
- Large, underserved therapeutic group.
Patients with inflammatory and immune-mediated disorders
Patients with inflammatory bowel disease are Protagonist Therapeutics, Inc.'s core immunology segment: IBD affects about 3.1 million people in the U.S. and roughly 7 million worldwide. They need durable control of flare-ups plus easy dosing, so the company’s oral peptide approach is built to improve adherence versus injected biologics.
- IBD is the main immunology target
- Need long-term disease control
- Oral dosing supports convenience
Protagonist Targets High-Need Hematology and IBD Markets
Protagonist Therapeutics, Inc. serves two main customer groups: Janssen Biotech for partnered drug development, and specialist prescribers plus patients in hematology and gastroenterology. Its most important end users are people with polycythemia vera, iron disorders, and inflammatory bowel disease, where the U.S. patient base is sizable and treatment need is still high.
| Segment | Key data |
|---|---|
| Janssen Biotech | Partner for icotrokinra |
| IBD patients | 3.1M U.S. |
| Polycythemia vera | ~44K U.S. |
Cost Structure
Clinical trial expenses
Clinical trial expenses are Protagonist Therapeutics, Inc.’s biggest cost driver because Phase II studies need patient recruitment, site monitoring, and data management. With multiple programs in play, each extra trial can add multimillion-dollar spend; industry benchmarks often put Phase II trials at roughly $7 million to $20 million each, so total R&D cash burn rises fast.
R&D personnel and laboratory costs
For Protagonist Therapeutics, Inc., R&D personnel and laboratory costs are the core fixed-cost base: scientists, assays, and lab infrastructure are needed to keep discovery and translational work moving. These costs recur each year through compensation and experiment spending, and in fiscal 2025 they remained the main driver of operating expense.
CMC and manufacturing spend
CMC and manufacturing spend is a major drag for Protagonist Therapeutics, Inc. because peptide synthesis, formulation, and quality testing are costly, and clinical supply chain work adds more expense. Tight manufacturing oversight is also non-negotiable for trial continuity, since any delay in supply can stop dosing and push back development.
Regulatory and IP expenses
Regulatory and IP costs are a steady drag for Protagonist Therapeutics, Inc.: IND work, FDA submissions, and GxP compliance add recurring overhead, while patent filing and maintenance protect the pipeline. U.S. patents generally last 20 years from filing, so these costs directly support long-term exclusivity and clinical progress.
These outlays are not optional; they fund trial access, label strategy, and freedom to operate as the company advances its programs.
- IND and FDA filing costs
- Ongoing compliance overhead
- Patent filing and maintenance
- Pipeline protection and value support
General and administrative costs
Protagonist Therapeutics, Inc. has ongoing general and administrative costs tied to being a public company: finance, legal, HR, audit, and SEC reporting. These overhead costs sit above the R&D base and rise as the organization adds staff, compliance work, and headquarters support.
- Finance and legal are fixed overhead.
- Public reporting adds recurring cost.
- Headcount growth lifts G&A spend.
Protagonist’s FY2025 Burn Is Driven by Trials, Labs, and Peptide CMC
Protagonist Therapeutics, Inc. spends most on R&D, led by Phase II trials, lab staff, and peptide CMC work. In FY2025, these remained the main operating cost drivers, while public-company G&A, FDA filings, and patent upkeep added steady overhead.
| Cost item | FY2025 role | Typical scale |
|---|---|---|
| Phase II trials | Main cash burn driver | $7m-$20m each |
| R&D staff and labs | Core fixed cost | Recurring yearly |
| G&A and compliance | Public-company overhead | Steady recurring |
Revenue Streams
Janssen collaboration revenue
Janssen collaboration revenue gives Protagonist Therapeutics non-dilutive cash through partner payments under its license deal. The Janssen pact included a 50 million dollar upfront payment and up to 655 million dollars in milestones, plus potential royalties, making collaboration revenue a core biotech funding stream.
Upfront and milestone fees
Protagonist Therapeutics, Inc. uses licensing deals with upfront cash and stage-based milestones to fund late-stage work; its 2024 Janssen pact for icotrokinra brought $50 million upfront and up to $1.7 billion in potential milestones. These payments are tied to clinical and regulatory progress, so they can support R&D before product sales start.
Future royalties
If Protagonist Therapeutics, Inc.’s partnered assets reach commercialization, royalties can flow on net sales, with rusfertide partnered to Takeda and advanced into Phase 3 in 2025. That fits the biotech licensing model: long-term upside from market sales, without Protagonist Therapeutics, Inc. needing to build manufacturing or a full sales force.
Future product sales
Future product sales could become a major revenue stream for Protagonist Therapeutics, Inc. only if it gains approval and launches an asset directly. For now, as a clinical-stage company, FY2025 product sales were $0, so this is still a potential, not current, driver.
- Approval first; sales later
- FY2025 product sales: $0
- Direct launch could change revenue mix
Additional licensing income
Additional licensing income lets Protagonist Therapeutics, Inc. monetize its peptide platform and pipeline rights beyond the Janssen pact, so it can pull in cash before full product sales. That matters because it diversifies funding and lowers dependence on one partner while turning scientific assets into near-term revenue.
- Licenses platform tech and pipeline rights
- Diversifies funding beyond Janssen
- Monetizes assets before commercialization
Protagonist’s Revenue Still Rides on Janssen, Not Product Sales
Protagonist Therapeutics, Inc. revenue is still partner-led: Janssen brought $50 million upfront, plus up to $1.7 billion in milestones and future royalties. FY2025 product sales were $0, so cash still comes from collaboration and licensing, not marketed drugs.
| Stream | FY2025 / Deal Data |
|---|---|
| Janssen upfront | $50 million |
| Potential milestones | Up to $1.7 billion |
| Product sales | $0 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.